Other News To Note
Wednesday, April 10, 2013
biOasis Technologies Inc., of Vancouver, British Columbia, said BT2111, a brain-penetrating conjugate of trastuzumab (Herceptin, Roche AG) and its Transcend vector designed to treat brain metatastsis of HER2-positive tumors, has moved into the next stage of preclinical development.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.